Furthermore, when these peptides were entrapped within the RADA16 hydrogel, they were released slowly allowing their interaction with the DPP-IV and ACE catalytic sites, suggesting that this strategy could be a viable platform for targeting metabolic diseases. Here, FAP is linked to metabolic disease.